Premium
Safety of long‐term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series
Author(s) -
GarcíaBustínduy M,
Escoda M,
Guimerá FJ,
Sáez M,
Dorta S,
Fagundo E,
SánchezGonzález R,
NodaCabrera A,
GarcíaMontelongo R
Publication year - 2004
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2004.00877.x
Subject(s) - medicine , retrospective cohort study , adverse effect , psoriasis , creatinine , surgery , dermatology
Background An intermittent short course of cyclosporin A (CyA) therapy is a good choice in the treatment of severe psoriasis. Nevertheless, some severe or resistant patients might benefit from long‐term treatment. Adverse effects of long‐term use of CyA are investigated and the results are compared with the literature. Patients and methods A retrospective study of adverse effects of CyA treatment in a group of 53 patients suffering from psoriasis. The mean treatment time was 31.4 ± 23.2 months with a minimum of 4 months to a maximum of 95 months, with very few short interruptions of treatment (from 2 to 5 months in five patients). Results The group consisted of 29 women and 24 men, ranging in age from 18 to 65 years, with an average age of 44.49 years. Arterial hypertension appeared in 45.3% of patients during treatment. Pharmacological treatment was required in 32% of these patients to control the condition. Serum creatinine levels were transiently elevated in 11.3% of the cases, but withdrawal of treatment was required in none of them. Discussion Long‐term CyA treatment might be necessary in some patients and this study shows that it could be sustained with a close follow‐up. This involves regular visits depending on each patient, as well as common test protocol and clinical evaluation. In conclusion, this retrospective study seems to confirm the relative safety of long‐term CyA treatment when patients are adequately monitored.